Publications of Lori Hazlehurst, PhD

Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities.
Shay G, Hazlehurst LA, Lynch CC.
J Mol Med (Berl). 2016;94(1):21-35.

PMC4707075.

A preclinical assay for chemosensitivity in multiple myeloma.
Khin ZP, Ribeiro ML, Jacobson T, Hazlehurst LA, Perez L, Baz R, Shain K, Silva AS.
Cancer Res. 2014;74(1):56-67.

PMC3915502.

MTI-101 (cyclized HYD1) binds a CD44 containing complex and induces necrotic cell death in multiple myeloma.
Gebhard AW, Jain P, Nair RR, Emmons MF, Argilagos RF, Koomen JM, McLaughlin ML, Hazlehurst LA.
Mol Cancer Ther. 2013;12(11):2446-2458.

PMC3859963.

Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases.
Schonbrunn E, Betzi S, Alam R, Martin MP, Becker A, Han H, Francis R, Chakrasali R, Jakkaraj S, Kazi A, Sebti SM, Cubitt CL, Gebhard AW, Hazlehurst LA, Tash JS, Georg GI.
J Med Chem. 2013;56(10):3768-3782.

PMC3714109.

The one-two punch: combination treatment in chronic myeloid leukemia.
Sweet KL, Hazlehurst LA, Pinilla-Ibarz J.
Crit Rev Oncol Hematol. 2013;88(3):667-679.


CRM1 inhibition sensitizes drug resistant human myeloma cells to topoisomerase II and proteasome inhibitors both in vitro and ex vivo.
Turner JG, Dawson J, Emmons MF, Cubitt CL, Kauffman M, Shacham S, Hazlehurst LA, Sullivan DM.
J Cancer. 2013;4(8):614-625.

PMC3805989.

Emerging strategies for targeting cell adhesion in multiple myeloma.
Nair RR, Gebhard AW, Emmons MF, Hazlehurst LA.
Adv Pharmacol. 2012;65:143-189.


Role of STAT3 in Transformation and Drug Resistance in CML.
Nair RR, Tolentino JH, Hazlehurst LA.
Front Oncol. 2012;2:30

PMC3355894.

Potentiation of Nilotinib-mediated cell death in the context of the bone marrow microenvironment requires a promiscuous JAK inhibitor in CML.
Nair RR, Tolentino JH, Argilagos RF, Zhang L, Pinilla-Ibarz J, Hazlehurst LA.
Leuk Res. 2012;36(6):756-763.

PMC3331955.

Acquisition of resistance toward HYD1 correlates with a reduction in cleaved alpha4 integrin expression and a compromised CAM-DR phenotype.
Emmons MF, Gebhard AW, Nair RR, Baz R, McLaughlin ML, Cress AE, Hazlehurst LA.
Mol Cancer Ther. 2011;10(12):2257-2266.

PMC3237739.

A database of reaction monitoring mass spectrometry assays for elucidating therapeutic response in cancer.
Remily-Wood ER, Liu RZ, Xiang Y, Chen Y, Thomas CE, Rajyaguru N, Kaufman LM, Ochoa JE, Hazlehurst LA, Pinilla-Ibarz J, Lancet J, Zhang G, Haura E, Shibata D, Yeatman T, Smalley KS, Dalton WS, Huang E, Scott E, Bloom GC, Eschrich SA, Koomen JM.
Proteomics Clin Appl. 2011;5(7-8):383-396.

PMC3530891.

Monitoring a nuclear factor-kappaB signature of drug resistance in multiple myeloma.
Xiang Y, Remily-Wood ER, Oliveira V, Yarde D, He L, Cheng JQ, Mathews L, Boucher K, Cubitt C, Perez L, Gauthier TJ, Eschrich SA, Shain KH, Dalton WS, Hazlehurst LA, Koomen JM.
Mol Cell Proteomics. 2011;10(11):M110

PMC3226396.

Tipifarnib-induced apoptosis in acute myeloid leukemia and multiple myeloma cells depends on Ca2+ influx through plasma membrane Ca2+ channels.
Yanamandra N, Buzzeo RW, Gabriel M, Hazlehurst LA, Mari Y, Beaupre DM, Cuevas J.
J Pharmacol Exp Ther. 2011;337(3):636-643.

PMC3101005.

The bone marrow microenvironment as a sanctuary for minimal residual disease in CML.
Nair RR, Tolentino J, Hazlehurst LA.
Biochem Pharmacol. 2010;80(5):602-612.

PMC3285111.

Signaling networks associated with BCR-ABL-dependent transformation.
Hazlehurst LA, Bewry NN, Nair RR, Pinilla-Ibarz J.
Cancer Control. 2009;16(2):100-107.


Detection of DNA damage induced by topoisomerase II inhibitors, gamma radiation and crosslinking agents using the comet assay.
Hazlehurst LA.
Methods Mol Biol. 2009;523:169-176.


HYD1-induced increase in reactive oxygen species leads to autophagy and necrotic cell death in multiple myeloma cells.
Nair RR, Emmons MF, Cress AE, Argilagos RF, Lam K, Kerr WT, Wang HG, Dalton WS, Hazlehurst LA.
Mol Cancer Ther. 2009;8(8):2441-2451.

PMC2761715.

Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation.
Shain KH, Yarde DN, Meads MB, Huang M, Jove R, Hazlehurst LA, Dalton WS.
Cancer Res. 2009;69(3):1009-1015.

PMC2680075.

Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition.
Turner JG, Marchion DC, Dawson JL, Emmons MF, Hazlehurst LA, Washausen P, Sullivan DM.
Cancer Res. 2009;69(17):6899-6905.

PMC2744372.

Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma.
Yarde DN, Oliveira V, Mathews L, Wang X, Villagra A, Boulware D, Shain KH, Hazlehurst LA, Alsina M, Chen DT, Beg AA, Dalton WS.
Cancer Res. 2009;69(24):9367-9375.

PMC4519834.

Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance.
Bewry NN, Nair RR, Emmons MF, Boulware D, Pinilla-Ibarz J, Hazlehurst LA.
Mol Cancer Ther. 2008;7(10):3169-3175.

PMC2676735.

Towards a framework for analysis of biophotonic images of mouse models of cancer.
Kamath V, Goldgof D, Argilagos R, Hazlehurst LA, Eschrich S.
Conf.Proc IEEE Eng Med Biol Soc. 2008;2008:3079-3082.


Proteomic contributions to personalized cancer care.
Koomen JM, Haura EB, Bepler G, Sutphen R, Remily-Wood ER, Benson K, Hussein M, Hazlehurst LA, Yeatman TJ, Hildreth LT, Sellers TA, Jacobsen PB, Fenstermacher DA, Dalton WS.
Mol Cell Proteomics. 2008;7(10):1780-1794.

PMC2559938.

The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance.
Meads MB, Hazlehurst LA, Dalton WS.
Clin Cancer Res. 2008;14(9):2519-2526.


Beta1 integrin mediated adhesion increases Bim protein degradation and contributes to drug resistance in leukaemia cells.
Hazlehurst LA, Argilagos RF, Dalton WS.
Br.J Haematol. 2007;136(2):269-275.


Bone marrow stromal cells prevent apoptosis of lymphoma cells by upregulation of anti-apoptotic proteins associated with activation of NF-kappaB (RelB/p52) in non-Hodgkin's lymphoma cells.
Lwin T, Hazlehurst LA, Li Z, Dessureault S, Sotomayor E, Moscinski LC, Dalton WS, Tao J.
Leukemia. 2007;21(7):1521-1531.


Cell adhesion induces p27Kip1-associated cell-cycle arrest through down-regulation of the SCFSkp2 ubiquitin ligase pathway in mantle-cell and other non-Hodgkin B-cell lymphomas.
Lwin T, Hazlehurst LA, Dessureault S, Lai R, Bai W, Sotomayor E, Moscinski LC, Dalton WS, Tao J.
Blood. 2007;110(5):1631-1638.

PMC1975846.

Topoisomerase II beta levels are a determinant of melphalan-induced DNA crosslinks and sensitivity to cell death.
Emmons M, Boulware D, Sullivan DM, Hazlehurst LA.
Biochem Pharmacol. 2006;72(1):11-18.


Cell adhesion to fibronectin (CAM-DR) influences acquired mitoxantrone resistance in U937 cells.
Hazlehurst LA, Argilagos RF, Emmons M, Boulware D, Beam CA, Sullivan DM, Dalton WS.
Cancer Res. 2006;66(4):2338-2345.


ABCG2 expression, function, and promoter methylation in human multiple myeloma.
Turner JG, Gump JL, Zhang C, Cook JM, Marchion D, Hazlehurst LA, Munster P, Schell MJ, Dalton WS, Sullivan DM.
Blood. 2006;108(12):3881-3889.

PMC1895461.

The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells.
Chen Q, Van der Sluis PC, Boulware D, Hazlehurst LA, Dalton WS.
Blood. 2005;106(2):698-705.

PMC1895179.

Targeting the bone marrow microenvironment in hematologic malignancies.
Dalton WS, Hazlehurst LA, Shain K, Landowski T, Alsina M.
Semin.Hematol. 2004;41(2 Suppl 4):1-5.


The cytoplasmic trafficking of DNA topoisomerase IIalpha correlates with etoposide resistance in human myeloma cells.
Engel R, Valkov NI, Gump JL, Hazlehurst LA, Dalton WS, Sullivan DM.
Exp Cell Res. 2004;295(2):421-431.


Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model.
Hazlehurst LA, Enkemann SA, Beam CA, Argilagos RF, Painter J, Shain KH, Saporta S, Boulware D, Moscinski L, Alsina M, Dalton WS.
Cancer Res. 2003;63(22):7900-7906.


Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death.
Hazlehurst LA, Landowski TH, Dalton WS.
Oncogene. 2003;22(47):7396-7402.


Cell adhesion-mediated drug resistance (CAM-DR) protects the K562 chronic myelogenous leukemia cell line from apoptosis induced by BCR/ABL inhibition, cytotoxic drugs, and gamma-irradiation.
Damiano JS, Hazlehurst LA, Dalton WS.
Leukemia. 2001;15(8):1232-1239.


Mechanisms associated with cell adhesion mediated drug resistance (CAM-DR) in hematopoietic malignancies.
Hazlehurst LA, Dalton WS.
Cancer Metastasis Rev. 2001;20(1-2):43-50.


Reduction in drug-induced DNA double-strand breaks associated with beta1 integrin-mediated adhesion correlates with drug resistance in U937 cells.
Hazlehurst LA, Valkov N, Wisner L, Storey JA, Boulware D, Sullivan DM, Dalton WS.
Blood. 2001;98(6):1897-1903.


Inhibition of JAK kinase activity enhances Fas-mediated apoptosis but reduces cytotoxic activity of topoisomerase II inhibitors in U266 myeloma cells.
Oshiro MM, Landowski TH, Catlett-Falcone R, Hazlehurst LA, Huang M, Jove R, Dalton WS.
Clin Cancer Res. 2001;7(12):4262-4271.


Multiple Myeloma: new insights and therapeutic approaches.
Anderson KC, Kyle RA, Dalton WS, Landowski T, Shain K, Jove R, Hazlehurst LA, Berenson J.
Hematology Am Soc Hematol Educ Program. 2000;147-165.


Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR).
Hazlehurst LA, Damiano JS, Buyuksal I, Pledger WJ, Dalton WS.
Oncogene. 2000;19(38):4319-4327.


Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines.
Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS.
Blood. 1999;93(5):1658-1667.


Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line.
Hazlehurst LA, Foley NE, Gleason-Guzman MC, Hacker MP, Cress AE, Greenberger LW, De Jong MC, Dalton WS.
Cancer Res. 1999;59(5):1021-1028.


Chromosome mediated gene transfer of drug resistance to mitoxantrone.
Hazlehurst LA, Gros P, Dalton WS.
Anticancer Res. 1998;18(2A):1005-1010.


Comparison of aza-anthracenedione-induced DNA damage and cytotoxicity in experimental tumor cells.
Hazlehurst LA, Krapcho AP, Hacker MP.
Biochem Pharmacol. 1995;50(7):1087-1094.


Correlation of DNA reactivity and cytotoxicity of a new class of anticancer agents: aza-anthracenediones.
Hazlehurst LA, Krapcho AP, Hacker MP.
Cancer Lett. 1995;91(1):115-124.